Natural interleukin-2 and lymphokine activated killer cells in the treatment of neuroblastoma in vitro and in vivo.
Berthold
F
F
Children's Hospital, University of Cologne, Köln, F.R.G.
Himmelmann
U
U
Pohl
U
U
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis; D002460:Cell Line; D002648:Child; D003602:Cytotoxicity, Immunologic; D004341:Drug Evaluation; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use* / Q000633:toxicity; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D009447:Neuroblastoma / Q000276:immunology* / Q000628:therapy; D010641:Phenotype; D011994:Recombinant Proteins
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D006680:HLA Antigens; D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma